WallStSmart

Oracle Corporation (ORCL)vsVistance Networks, Inc. (VISN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Oracle Corporation generates 3285% more annual revenue ($67.36B vs $1.99B). VISN leads profitability with a 365.4% profit margin vs 25.4%. ORCL appears more attractively valued with a PEG of 0.86. ORCL earns a higher WallStSmart Score of 76/100 (B+).

ORCL

Strong Buy

76

out of 100

Grade: B+

Growth: 8.0Profit: 9.0Value: 5.3Quality: 3.0
Piotroski: 2/9Altman Z: 0.68

VISN

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 6.0Value: 4.0Quality: 6.5
Piotroski: 5/9Altman Z: 0.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ORCLSignificantly Overvalued (-42.6%)

Margin of Safety

-42.6%

Fair Value

$105.36

Current Price

$150.28

$44.92 premium

UndervaluedFair: $105.36Overvalued

Intrinsic value data unavailable for VISN.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ORCL6 strengths · Avg: 9.2/10
Market CapQuality
$432.88B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
40.2%10/10

Every $100 of equity generates 40 in profit

Operating MarginProfitability
36.2%10/10

Strong operational efficiency at 36.2%

Profit MarginProfitability
25.4%9/10

Keeps 25 of every $100 in revenue as profit

PEG RatioValuation
0.868/10

Growing faster than its price suggests

Revenue GrowthGrowth
20.6%8/10

Revenue surging 20.6% year-over-year

VISN4 strengths · Avg: 10.0/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Profit MarginProfitability
365.4%10/10

Keeps 365 of every $100 in revenue as profit

EPS GrowthGrowth
1697.0%10/10

Earnings expanding 1697.0% YoY

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Areas to Watch

ORCL4 concerns · Avg: 2.8/10
Price/BookValuation
11.5x4/10

Trading at 11.5x book value

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Free Cash FlowQuality
$-1.87B2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
0.682/10

Distress zone — elevated risk

VISN4 concerns · Avg: 2.5/10
Market CapQuality
$1.48B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
2.2%3/10

Operating margin of 2.2%

PEG RatioValuation
2.942/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.4%2/10

Revenue declined 1.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : ORCL

The strongest argument for ORCL centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 25.4% and operating margin at 36.2%. Revenue growth of 20.6% demonstrates continued momentum.

Bull Case : VISN

The strongest argument for VISN centers on Price/Book, Profit Margin, EPS Growth. Profitability is solid with margins at 365.4% and operating margin at 2.2%.

Bear Case : ORCL

The primary concerns for ORCL are Price/Book, Piotroski F-Score, Free Cash Flow. Debt-to-equity of 3.67 is elevated, increasing financial risk.

Bear Case : VISN

The primary concerns for VISN are Market Cap, Operating Margin, PEG Ratio.

Key Dynamics to Monitor

ORCL profiles as a growth stock while VISN is a declining play — different risk/reward profiles.

VISN carries more volatility with a beta of 1.92 — expect wider price swings.

ORCL is growing revenue faster at 20.6% — sustainability is the question.

VISN generates stronger free cash flow (-75M), providing more financial flexibility.

Bottom Line

ORCL scores higher overall (76/100 vs 62/100), backed by strong 25.4% margins and 20.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Oracle Corporation

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

Oracle is an American multinational computer technology corporation headquartered in Austin, Texas. The company was formerly headquartered in Redwood Shores, California until December 2020 when it moved its headquarters to Texas. The company sells database software and technology, cloud engineered systems, and enterprise software products, particularly its own brands of database management systems.

Visit Website →

Vistance Networks, Inc.

TECHNOLOGY · COMMUNICATION EQUIPMENT · USA

Gyroscope Therapeutics Holdings plc, a clinical-stage gene therapy company, develops gene therapy products to treat patients with eye diseases. The company is headquartered in Stevenage, the United Kingdom.

Want to dig deeper into these stocks?